Effects of Vaccination on Invasive Pneumococcal Disease in South Africa

Invasive pneumococcal disease is an important cause of severe illness. In South Africa, a national program to vaccinate children with the conjugated pneumococcal vaccine resulted in a substantial decline in invasive pneumococcal disease countrywide, including in adults. The majority of deaths associ...

Full description

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 371; no. 20; pp. 1889 - 1899
Main Authors: von Gottberg, Anne, de Gouveia, Linda, Tempia, Stefano, Quan, Vanessa, Meiring, Susan, von Mollendorf, Claire, Madhi, Shabir A, Zell, Elizabeth R, Verani, Jennifer R, O’Brien, Katherine L, Whitney, Cynthia G, Klugman, Keith P, Cohen, Cheryl
Format: Journal Article
Language:English
Published: Waltham, MA Massachusetts Medical Society 13.11.2014
Subjects:
Adult
Age
Bacterial diseases
Biological and medical sciences
Children
Children & youth
General aspects
Heptavalent Pneumococcal Conjugate Vaccine
HIV
HIV Infections - complications
Human bacterial diseases
Human immunodeficiency virus
Humans
Immunization
Incidence
Infant
Infants
Infectious diseases
Medical sciences
Penicillin Resistance
Pneumococcal Infections - epidemiology
Pneumococcal Infections - microbiology
Pneumococcal Infections - prevention & control
Pneumococcal Vaccines - administration & dosage
Pneumonia
Population Surveillance
Serogroup
Serotypes
South Africa - epidemiology
Staphylococcal infections, streptococcal infections, pneumococcal infections
Streptococcus infections
Streptococcus pneumoniae - classification
Vaccination
Vaccines
Vaccines, Conjugate
South Africa
Africa
Infection
Prevention
Medicine
Immunoprophylaxis
Streptococcal infection
Vaccination
Bacteriosis
Pneumococcal infection
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Invasive pneumococcal disease is an important cause of severe illness. In South Africa, a national program to vaccinate children with the conjugated pneumococcal vaccine resulted in a substantial decline in invasive pneumococcal disease countrywide, including in adults. The majority of deaths associated with childhood pneumococcal disease occur in Africa. 1 , 2 In randomized trials conducted in Africa, 3 , 4 a pneumococcal conjugate vaccine (PCV) was given to infants when they were 6, 10, and 14 weeks of age, without a booster dose. The vaccine showed efficacy for the prevention of invasive pneumococcal disease caused by the nine serotypes contained in the vaccine among infants who were not infected with the human immunodeficiency virus (HIV) (83% efficacy; 95% confidence interval [CI], 39 to 97) and among infants who were infected with HIV (65% efficacy; 95% CI, 24 to 86). 3 , . . .
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1401914